€6.28
Your prediction
Actinium Pharmaceuticals Inc. Stock
Pros and Cons of Actinium Pharmaceuticals Inc. in the next few years
Pros
Cons
Performance of Actinium Pharmaceuticals Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Actinium Pharmaceuticals Inc. | -3.010% | -25.856% | 1.290% | -26.118% | 38.938% | 0.480% | - |
| Immunic Inc. | 7.710% | -9.618% | -2.951% | -19.565% | -17.203% | -90.067% | - |
| NanoViricides Inc. | 1.890% | -7.692% | 3.846% | -14.961% | 14.286% | -69.457% | -76.794% |
| Ocuphire Pharma Inc. | 1.320% | -1.205% | -6.606% | -70.182% | -41.324% | - | - |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.This analysis presents an overview of the financial performance of Actinium Pharmaceuticals, an industry leader in Biotechnology & Medical Research. Its financial statements and ratios reveal an intricate blend of strengths and weaknesses, which, to the keen observer, offer various avenues for exploration and critical assessment.
Notabily, the company's market capitalization stands at 122.93 million USD. Well, any entrepreneur would attest that a hefty market capitalization, such as Actinium's, suggests that the market holds a strong confidence in a company’s long-term prospects. Ergo, this benchmark underscores Actinium’s potential to spark its investors' trust.
Call it a cliché, but it's not all about the money. However, business, specifically in Biotechnology & Medical Research, often requires grand financial floatation devices. Actinium has an enterprise value of 37.65 million, a respectable figure in its industry. This figure indicates a commendable ability on Actinium's part to generate revenues, displaying significant proficiency in business operations quite a relief to both existing and potential investors.